GH Research PLC GHRS 深 滬
已收盤 10-17 16:00:00 美东时间
13.49
-0.330
-2.39%
華盛通- 最 高14.31
- 今 開13.80
- 成交量 19.42万股
- 最 低 13.15
- 昨 收 13.82
- 總市值 8.37亿
- 52周最高 20.50
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 6.72
- 委 比 19.30%
- 總股本 6202.94万
- 歷史最高 30.43
- 量 比 0.63
- 振 幅 8.39%
- 歷史最低 5.05
- 每 手 1
- 風險率 2.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多GH Research’s GH001 Trial Results to be Presented at ACNP Meeting
The latest announcement is out from GH Research ( ($GHRS) ). GH Research PLC an...
10-17 19:29
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
Depression-Focused GH Research Shares Could See Significant Upside: Analyst
GH Research's GH001 shows strong Phase 2 results for treatment-resistant depression, with FDA issues nearly resolved and $1.9 billion U.S. potential.
10-14 02:07
GH Research to Present Long-Term Data on Depression Treatment at 38th European Neuropsychopharmacology Congress
GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of a
10-09 19:14
GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress
GH Research PLC, a clinical-stage biopharmaceutical company, announced the acceptance of a presentation and posters at the 38th Annual European College of Neuropsychopharmacology Congress (ECNP) in Amsterdam. The presentation will highlight long-term safety and efficacy data from a Phase 2b open-label extension (OLE) study of GH001 in treatment-resistant depression (TRD). Positive safety findings and rapid-acting potential of GH001 reinforce its ...
10-09 11:00
Shares of psychedelic companies are trading higher after a GOP senator stated he's "confident" that under the Trump administration, lawmakers will help secure alternative treatment options for military veterans, including access to psychedelic medicine.
Shares of psychedelic companies are trading higher after a GOP senator stated h...
08-26 02:53
GH Research GAAP EPS of -$0.15
GH Research press release (NASDAQ:GHRS): Q2 GAAP EPS of -$0.15. Cash, cash equivalents, short- and long-term investments, and interest receivable were $510.9 million as of June 30, 2025. More on GH...
08-07 21:34
GH Research Q2 EPS $(0.15) Beats $(0.21) Estimate
GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.21) by 30.23 percent. This is a 25 percent increase over losses of $(0.20) per share from the same
08-07 19:15
GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates
GH Research PLC reported financial results for Q2 2025, including $308.7M in cash, and provided updates on its pivotal program for 2026. The GH001 clinical trial met its primary endpoint with a 73% remission rate at 6 months, showing favorable safety and tolerability. The company also announced progress on GH002 and ongoing FDA engagement for IND responses.
08-07 11:00
GH Research Announces Global Pivotal Program Plans and Further Development Updates
GH Research PLC has provided updates on its business and upcoming milestones. Engagement with the FDA on the complete response to the IND for GH001 is ongoing, with only one hold topic remaining. Phase 2b TRD trial results show a 73% remission rate at 6 months with no serious adverse events. GH002 Phase 1 results demonstrate safety and rapid effects, with an IND expected in Q4 2025. The global pivotal program is on track to commence in 2026.
07-23 12:00
